Litcius/Paper detail

Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial

Amy S. Paller, Eric L. Simpson, Elaine C. Siegfried, Michael J. Cork, Andreas Wollenberg, Peter D. Arkwright, Weily Soong, Mercedes E. González, Lynda C. Schneider, Robert Sidbury, Benjamin Lockshin, Steven M Meltzer, Zhixiao Wang, Leda Mannent, Nikhil Amin, Yiping Sun, Elizabeth Laws, Bolanle Akinlade, Myles Dillon, Matthew P. Kosloski, Mohamed Kamal, Ariane Dubost-Brama, Naimish Patel, David M. Weinreich, George D. Yancopoulos, John T. O’Malley, Ashish Bansal, A. Pepper, Amy S. Paller, Benjamin Lockshin, David J. Cohen, David M. Pariser, Elaine C. Siegfried, Eric L. Simpson, Jeffrey Leflein, Jeffrey S. Weinberg, John Browning, Joyce Teng, Lara Wine Lee, Lawrence Sher, Lucia Z. Diaz, Lynda C. Schneider, Mercedes E. González, Ned T. Rupp, Peck Y. Ong, Robert Cartwright, Robert Sidbury, Weily Soong, Andreas Pinter, Andreas Wollenberg, Christina Schnopp, Michael J. Cork, Peter D. Arkwright, Anna Korkosz, Dorota Bystrzanowska, Ewa Sygula, Jacek Zdybski, Kamila Padlewska

2022The Lancet267 citationsDOIOpen Access PDF

Topics & Concepts

MedicineAtopic dermatitisEczema Area and Severity IndexPlaceboClinical endpointDupilumabSCORADRandomized controlled trialConcomitantAdverse effectClinical trialRandomizationPediatricsInternal medicineDermatologyDermatology Life Quality IndexDiseaseAlternative medicinePathologyDermatology and Skin DiseasesPsoriasis: Treatment and PathogenesisAllergic Rhinitis and Sensitization
Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial | Litcius